VGM Research Note — Coverage Needs Fresh Evidence
VGM reached $10.52 with weak momentum, while stale coverage data makes the August distribution declaration the next important piece of evidence.
Research Notes
RCL Research Note — The October Evidence Test
Royal Caribbean retains a strong operating record, but valuation and market extension make October unit economics the next decisive evidence.
XOVR Research Note — The Proxy Faces Live Transmission
XOVR’s August decline suggests SpaceX volatility is reaching the wrapper, with additional supply events keeping redemption resilience in focus.
AAPL Research Note — The Multiple Carries the Risk
Apple’s cash generation remains formidable, but the October report and leadership transition will test a valuation built on multiple durability.
LLY Research Note — Proof After the Gap
Lilly’s post-earnings evidence preserved the franchise case, but recurring margins and oral-program progress still have to support the valuation.
GLD Research Note — A Broken Price Scale
GLD’s macro thesis survived the August review, but conflicting price series block fresh conclusions about trend, levels and volatility.
COST Research Note — Renewal Nears Its Ceiling
Costco’s 92.2% renewal rate remains elite, but September results must show how member growth and margins can support the premium multiple.
ACGL Research Note — Premium Growth Faces a Test
Slower premium growth, catastrophe exposure and the rate path set the evidence test for Arch Capital through October.
SPCX Research Note — Evidence Meets Supply
SpaceX operating progress meets SPCX’s unresolved post-IPO tape as first earnings and a large August share release test public-market demand.
WST Research Note — Good Quarter, Harder Proof
West Pharmaceutical’s strong quarter meets a harder test from valuation, market structure and unresolved oral-drug substitution risk.